Deferoxamine (Deferoxamine B) 是一种铁螯合剂 (结合 Fe(III) 和许多其他金属阳离子)，被广泛用于减少铁在组织中的积累和沉积。Deferoxamine 具有较好的抗氧化活性，可上调HIF-1α水平。Deferoxamine 还具有抗增殖活性，能诱导癌细胞凋亡和自噬。Deferoxamine 可用于糖尿病、神经退行性疾病以及抗癌和抗 COVID-19 的研究。
| 生物活性 | Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulatesHIF-1αlevels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induceapoptosisandautophagyincancercells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5]. |
体外研究
(In Vitro) | Deferoxamine (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells[1].
Deferoxamine (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels[2].
Deferoxamine (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs[3].
Deferoxamine (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs[3].
Deferoxamine (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs[3].
Deferoxamine (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells[4].
Western Blot Analysis[1] | Cell Line: | MEFs cells | | Concentration: | 1 mM | | Incubation Time: | 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions) | | Result: | Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.
Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions. |
Western Blot Analysis[2] | Cell Line: | HepG2 cells | | Concentration: | 100 μM | | Incubation Time: | 24 h | | Result: | Showed a twofold increase of InsR mRNA levels in cells.
Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM. |
Cell Proliferation Assay[3] | Cell Line: | TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model)) | | Concentration: | 5, 10, 25, 50, 100 μM | | Incubation Time: | 7 days (TAMSCs); 9 days (BMMSCs). | | Result: | Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 μM dose. |
Apoptosis Analysis[3] | Cell Line: | TAMSCs, BMMSCs | | Concentration: | 5, 10, 25, 50, 100 μM | | Incubation Time: | 7 days | | Result: | Exhibited proapoptotic effect on TAMSCs and BMMSCs cells. |
Western Blot Analysis[3] | Cell Line: | TAMSCs, BMMSCs | | Concentration: | 10 μM | | Incubation Time: | 3 days | | Result: | Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs. |
Cell Autophagy Assay[4] | Cell Line: | SH-SY5Y cells | | Concentration: | 100 μM | | Incubation Time: | 24 h | | Result: | Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related geneBeclin 1was suppressed byBeclin 1siRNA transfection.
Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy. |
|
体内研究
(In Vivo) | Deferoxamine (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice[1].
Deferoxamine (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo[2].
| Animal Model: | Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)[1]. | | Dosage: | 560.68 mg/per (10 uL of 1 mM) | | Administration: | Drip-on; once daily for 21 days. | | Result: | Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model. |
| Animal Model: | Male Sprague-Dawley rats (180-200 g)[2]. | | Dosage: | 200 mg/kg | | Administration: | Intraperitoneal injection; daily for 2 weeks. | | Result: | Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com